AnaptysBio Inc. (ANAB)

AI Score

Unlock

18.95

0.30 (1.61%)

At close: Mar 28, 2025, 3:59 PM

18.93

-0.11%

After-hours: Mar 28, 2025, 06:23 PM EDT

1.61% (1D)

Bid	17.61
Market Cap	581.29M
Revenue (ttm)	98.63M
Net Income (ttm)	-156.92M
EPS (ttm)	-5.12
PE Ratio (ttm)	-3.7
Forward PE	-3.06
Analyst	Buy

Ask	19.58
Volume	724,683
Avg. Volume (20D)	1,020,480
Open	18.61
Previous Close	18.65
Day's Range	18.61 - 19.60
52-Week Range	12.21 - 41.31
Beta	0.03

About ANAB

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 26, 2017

Employees 136

Stock Exchange NASDAQ

Ticker Symbol ANAB

Website https://www.anaptysbio.com

Full Company Profile

Analyst Forecast

According to 10 analyst ratings, the average rating for ANAB stock is "Buy." The 12-month stock price forecast is $38, which is an increase of 100.47% from the latest price.

Stock Forecasts

Next Earnings Release

AnaptysBio Inc. is scheduled to release its earnings on May 8, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

5 days ago

+9.54%

AnaptysBio shares are trading higher after the com... Unlock content with Pro Subscription

1 month ago

+30.45%

AnaptysBio shares are trading higher after the company announced statistically significant week 12 data from the Phase 2b trial of rosnilimab in moderate-to-severe rheumatoid arthritis.

News

4 days ago · zacks.com

AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last?

AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

1 month ago · zacks.com

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $1.61. This compares to loss of $1.59 per share a year ago.

1 month ago · zacks.com

Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?

Here is how AnaptysBio, Inc. (ANAB) and AtriCure (ATRC) have performed compared to their sector so far this year.

1 month ago · zacks.com

AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?

AnaptysBio (ANAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in...